Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02387866 · ClinicalTrials.gov registry record · Phase 1
PK and Safety Study of AG-221 in Healthy Male Japanese Subjects and Healthy Male Caucasian Subjects
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT02387866 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 62 participants.
The verdict
NCT02387866, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
This is a single ascending dose, open-label study that will evaluate the pharmacokinetics and safety of the AG-221 compound in normal, healthy volunteer male subjects (both Japanese and Caucasian).
Interventions
- DRUG AG-221
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2015-03-02 |
| Est. Completion | 2015-07-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02387866
The ClinicalTrials.gov registry entry for NCT02387866 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AG-221 is the first listed.
NCT02387866 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02387866 about?
NCT02387866 is a clinical study titled "PK and Safety Study of AG-221 in Healthy Male Japanese Subjects and Healthy Male Caucasian Subjects". This is a single ascending dose, open-label study that will evaluate the pharmacokinetics and safety of the AG-221 compound in normal, healthy volunteer male subjects (both Japanese and Caucasian).
What is the current status of trial NCT02387866?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2015-03-02. Estimated completion is 2015-07-27.
What interventions are being tested in trial NCT02387866?
The interventions under investigation include: AG-221 (DRUG).
Who is sponsoring clinical trial NCT02387866?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.